Today: 29 June 2026
Westpac share price hits a fresh 52-week high as ASX banks run — CPI is the next big test
20 February 2026
1 min read

Westpac share price hits a fresh 52-week high as ASX banks run — CPI is the next big test

Sydney, Feb 20, 2026, 17:12 AEDT — Market shut down for the day

Westpac Banking Corp (WBC.AX) finished Friday at A$42.54, up 1.6% and touching its highest level in a year. Investors kept piling into the big Australian banks, pushing Westpac up roughly 4.3% across the last two sessions after Thursday’s 2.7% gain.

This shift carries weight—banks have been propping up the benchmark lately, and when traders rush for quick “Australia” exposure, Westpac stands out as a go-to pick. With a few big banks and miners driving the gains, the whole market is now more exposed if those leaders slip. Market Index

The real test comes when the macro calendar gets crowded again. With the inflation print on deck next week, that’s the key local event. It could easily move the dial on where rates land — crucial for banks, since their earnings ride on interest margins.

The S&P/ASX 200 dipped roughly 0.2% to finish at 9,069.5 this Friday. Westpac stood out with stronger gains.

Westpac’s latest update hasn’t faded into the background just yet. The bank’s first-quarter investor pack last week showed an unaudited statutory net profit of A$1.9 billion. Core net interest margin? Down 3 basis points to 1.79%. That’s the gap between loan earnings and deposit payouts. “We are optimistic on the outlook for the economy and expect demand for both business and household credit to remain resilient,” said chief executive Anthony Miller. Westpac

Thursday brought fresh labor market numbers for those tracking rates. January’s jobless rate stuck at 4.1%, employment climbed by 18,000, according to the Australian Bureau of Statistics. Full-time positions added 50,000; part-time jobs slipped by 33,000. “The unemployment rate remained steady at 4.1 per cent in January,” said Sean Crick, head of labour statistics at the ABS. Australian Bureau of Statistics

Westpac economists stuck to a more upbeat view on growth Friday, shrugging off the turbulence in last year’s data. “Overall, the signal is clear: leading indicators are outperforming and point to further gains in activity,” wrote senior economist Pat Bustamante. The bank’s nowcast suggests GDP climbed about 0.9% in the December quarter. Westpac IQ

Still, there’s a vulnerability here—funding and deposit costs. According to a recent Jarden note highlighted by FNArena, major banks might be exaggerating how much they gain from those cheaper retail deposits. Repricing could squeeze net interest margins. Jarden has Westpac at “Underweight”—that’s less than the benchmark position. FNArena.com

Westpac’s next key update won’t hit until further down the track. Its financial half closes out on March 31, and the bank has slated May 5 for both interim earnings and its dividend release, the investor calendar shows.

Traders are eyeing the inflation calendar. The ABS schedules January CPI for Feb. 25, 11:30 a.m. AEDT. A curveball in those numbers could force a fast rethink on rates, shaking up the bid for banks.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Guardant Health (GH) Stock Valuation Insights After 193% One-Year Gain
    June 28, 2026, 6:40 PM EDT. Guardant Health (GH) shares have surged 193.4% over the past year to around $149, raising questions about potential future gains. Despite strong price momentum, a Discounted Cash Flow (DCF) analysis estimates an intrinsic value near $159.10 per share, indicating the stock trades at a modest 6.2% discount. However, the company currently posts negative free cash flow ($232.49 million last twelve months) with projections to turn positive by 2030, reflecting ongoing challenges. Guardant Health scores just 1 out of 6 on valuation metrics, signaling caution for investors. The Price-to-Sales ratio is considered more relevant due to inconsistent profitability. Overall, GH appears fairly valued but market sentiment and fundamentals should be closely monitored for changes.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Next Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Go toTop